Skip to main content

BioCommunique Article

Biocom continues to work alongside member companies and the Pharmaceutical Manufacturers and Research Association opposing AB 824.

State Legislature Works Up To Recess

  • 2019-07-11T20:02:00.000+0000
  • California
  • Author: Jimmy Jackson

As the State Legislature heads towards its monthlong recess that begins this Friday, Biocom is continuing to work as part of an opposition coalition working with member companies and the Pharmaceutical Manufacturers and Research Association opposing AB 824, legislation which would set a presumption in law that any patent challenge settlement, whether executed in California or not, is anti-competitive and subject to significant penalties, and furthermore shifts the legal responsibility to the companies to prove a settlement is not anti-competitive.

The latest version of the bill passed the Senate Judiciary Committee on July 9, and now heads to the Senate Appropriations Committee. We will continue to keep you abreast of developments as this important bill progresses in the Legislature.

As reported earlier this year, a tax proposal on opioid manufacturers (AB 1468) by Assemblyman Kevin McCarty has been awaiting a vote on the Assembly floor since May, often a sign the author has not secured commitments for sufficient votes for the bill to pass. This bill as revised establishes a set pool of $50 million to be collected from opioid manufacturers and wholesalers doing business in California.

This is Biocom’s original letter of opposition citing concerns with the bill, some of which have been addressed. Unfortunately, the bill still ignores the fact that several recent federal streams of funding have started coming to California for the fight against opioid addiction and there has not been sufficient time to access their success or remaining gaps, and Biocom remains opposed to AB 1468.